美教授：中国这项技术也在反超，令人兴奋

Core Insights - The article discusses the advancements in brain-computer interface (BCI) technology, particularly focusing on the "Beinao-1" chip developed in China, which has shown promising results in clinical trials for patients with conditions like ALS [1][5][10]. Group 1: Technology Development - The "Beinao-1" chip is a wireless BCI that allows patients to communicate their thoughts through text on a screen, demonstrating high accuracy in decoding brain signals [1][5]. - The Beijing Institute for Brain Science and Brain-like Research (CIBR) has initiated clinical trials, with plans to implant the chip in 50 to 100 patients in the coming year [1][5]. - The technology is described as "semi-invasive," allowing for sufficient signal capture without the higher risks associated with more invasive methods used by some U.S. companies [4][10]. Group 2: Market Potential - The global BCI market was valued at approximately $2.6 billion last year and is projected to grow to $12.4 billion by 2034 [7]. - The demand for BCI technology is described as "very strong," with numerous requests from potential patients [1][5]. Group 3: Competitive Landscape - Experts indicate that while the U.S. has historically led in BCI technology, China is rapidly catching up and even leading in certain areas [2][10]. - The article highlights the competitive nature of BCI research between China and the U.S., with both countries recognizing the technology's potential [2][7]. - Comparisons are made between China's "Beinao-1" and U.S. companies like Neuralink, noting differences in implantation techniques and signal recording methods [10]. Group 4: Research and Collaboration - The NeuCyber NeuroTech company, incubated by CIBR, focuses on developing BCI products like "Beinao-1" [4]. - Recent collaborations in Shanghai have also yielded breakthroughs in BCI technology, further enhancing the prospects for patients with speech impairments [10].